DRUG NEWS: Arixtra may be safer for ACS patients

November 2005 
Volume 35  Number 11
Pages 30 - 30
  PDF Version Available!


In a study of 20,000 patients experiencing acute coronary syndrome in 41 countries, the newer anticoagulant fondaparinux (Arixtra) proved just as effective as enoxaparin (Lovenox) at preventing blood clots while cutting the risk of bleeding by half. Bleeding is the most serious adverse reaction associated with anticoagulants.

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events